Previous 10 | Next 10 |
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of -CHF0.09 beats by CHF0.05 ; GAAP EPS of -CHF0.11 beats by CHF0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19 Ongoing strong financial position with CHF 277.9 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones Added ne...
Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A lead anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat P...
AC Immune (NASDAQ: ACIU ): FY Non-GAAP EPS of CHF0.64; GAAP EPS of CHF0.64 misses by CHF0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestones Received CHF 110 million in upfront and development milestone payments and a USD 50 million equity note in 2019 as a result o...
AC Immune SA ( ACIU +3.5% ) announces that it has earned a second milestone payment of CHF 10M ($10.2M) from collaboration partner Eli Lilly ( LLY -3.2% ) triggered by the advancement of its small molecule Morphomer Tau aggregation inhibitor program. It expects to receive the monies by...
CHF 10 million milestone recognizes development progress Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion LAUSANNE, Switzerland, March 23, 2020 (GLOBE NEWSWIRE) -- AC Immun...
LAUSANNE, Switzerland, March 20, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced Dr. Juan Fortea, an internationally renowned neurologist with a specifi...
This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...
LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in Lo...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...